Retatrutide Research: Mechanism, Receptor Targets & Published Studies

What is retatrutide (LY3437943)?

What is retatrutide? It is a synthetic single-molecule peptide investigated by Eli Lilly as a triple receptor agonist, and known in the primary literature by its development code LY3437943. The distinguishing idea, as described in the discovery paper, is that one engineered peptide was designed to act at three separate receptors rather than one or two.

It is important to state plainly what its status is: retatrutide is an investigational compound. It has been examined only within clinical trials and is not approved for human use by any regulator. In research catalogues it is supplied as a lyophilized powder for laboratory work. Everything below describes molecule properties and what published studies looked at — nothing here is a use, a benefit, or an outcome a reader should expect.

Molecule properties

The molecule facts are drawn from the discovery and pharmacokinetic literature. Coskun et al. (2022) describe retatrutide as a synthetic peptide of roughly 39 amino acids engineered from a GIP-based backbone, with non-coded residues — such as aminoisobutyric acid (Aib) substitutions — introduced to improve stability against enzymatic degradation. The design also carries a C20 fatty-diacid side chain that enables reversible binding to circulating albumin, a common strategy for extending a peptide’s residence time in plasma.

Consistent with that design, Urva et al. (2022) reported a plasma half-life of approximately six days — a property that the trials associated with a once-weekly administration schedule. That half-life is recorded here strictly as a measured molecule property, not as any form of dosing guidance. As with other research peptides in the catalogue, retatrutide is handled as a dry lyophilized powder, which is its stable form, and its identity and purity for any given batch are documented on that batch’s Certificate of Analysis rather than assumed.

How retatrutide works — the triple-agonist mechanism

The retatrutide mechanism described in the discovery pharmacology is agonism at three receptors by one molecule. Each line below is framed as what researchers characterised in model systems, not as an effect in any reader:

• GLP-1 receptor (GLP-1R) — the incretin and satiety-signalling target shared with the earlier single agonists; the pathway most studied in the incretin-peptide class.
• GIP receptor (GIPR) — the glucose-dependent insulinotropic polypeptide receptor; Coskun et al. reported that the molecule carries relatively higher GIPR activity in vitro.
• Glucagon receptor (GCGR) — the distinguishing third target; preclinical work attributed a portion of the energy-expenditure signalling examined in models to GCGR engagement.

The research rationale, stated neutrally, is that engaging all three receptors with a single molecule was studied as a way to combine incretin and glucagon-pathway signalling within one investigational agent. That is a description of a scientific hypothesis under study — not a promise of any result, and not a claim that the combination produces a benefit.

Receptor targets at a glance

For quick reference, the three receptors and the pathway each is associated with in the literature:

• GLP-1R — incretin / satiety signalling researchers associate with this pathway.
• GIPR — incretin signalling; reported relatively higher in-vitro activity for this molecule.
• GCGR — glucagon-pathway signalling; the third target that defines the triple-agonist profile.

This is molecule-mechanism reference only. The three-molecule head-to-head across the incretin class — single vs dual vs triple framing — lives on the sibling comparison page; see Retatrutide vs Semaglutide vs Tirzepatide to compare receptor targets across the GLP class, which this page does not restate.

What published retatrutide studies investigated

The primary literature is best read chronologically, and strictly as what each study examined rather than as results a reader should expect:

• Coskun et al., 2022 (Cell Metabolism) — the discovery-to-proof-of-concept paper that characterised LY3437943 receptor binding and preclinical pharmacology; the source for the molecule-design and receptor-activity descriptions above.
• Urva et al., 2022 (The Lancet) — a phase 1b multiple-ascending-dose study in people with type 2 diabetes that characterised pharmacokinetics, including the reported ~6-day half-life.
• Jastreboff et al., 2023 (NEJM) — a phase 2 trial in adults with obesity; the investigators studied the molecule in that population.
• Rosenstock et al., 2023 (The Lancet) — a phase 2 trial in adults with type 2 diabetes.
• Sanyal et al., 2024 (Nature Medicine) — a phase 2a trial that examined liver-fat endpoints in metabolic dysfunction-associated steatotic liver disease (MASLD) by MRI-PDFF imaging.

Each of these describes a specific study population and a set of measured variables; none is presented here with outcome figures, because the purpose of this page is to record what the trials investigated, not to translate their endpoints into expectations. A phase 3 program is under way — the TRIUMPH obesity trials (including TRIUMPH-3, NCT05882045) and the TRANSCEND-T2D diabetes program — and that is noted only as investigational status, not as any result.

Investigational status

To be explicit, because the SERP around this molecule is full of outcome claims: retatrutide is an investigational compound. It is not approved for human use by the FDA, the EMA, BPOM (Indonesia) or any other regulator. The endpoints being examined in the trials named above do not constitute established effects, and the answer to “is retatrutide FDA approved?” is simply no. Material offered here is supplied for laboratory research use only and is not for human or veterinary use.

Research-grade sourcing, quality & verification

For laboratory research use only, retatrutide is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spectrometry identity confirmation. Because a mechanism summary is only as meaningful as the identity of the material behind it, the exact batch received can be checked directly: enter the lot number on the self-serve verify tool to pull that batch’s COA, and see how to read a COA for what each line on the certificate means.

Frequently asked questions

Literature cited

1. Coskun T, et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept.” Cell Metabolism. 2022;34(9):1234–1247.
2. Urva S, et al. “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multiple-ascending-dose trial.” The Lancet. 2022;400(10366):1869–1881.
3. Jastreboff AM, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine. 2023;389:514–526.
4. Rosenstock J, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial.” The Lancet. 2023;402(10401):529–544.
5. Sanyal AJ, et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nature Medicine. 2024.
6. Program status (named neutrally): TRIUMPH phase 3 obesity program (incl. TRIUMPH-3, NCT05882045); TRANSCEND-T2D phase 3 diabetes program — ongoing investigational status only.